Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6783764 | 0.78 | SLC6A4 (0.44) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL6926596 | 0.77 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL2578334 | 0.72 | HTR2C (0.39) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL6925353 | 0.71 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL11836887 | 0.71 | HTR2C (0.60) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL15000426 | 0.70 | HTR2C (0.47) | SLC6A2SLC6A4SLC6A3HTR2CHTR6 | |
| SCHEMBL11827483 | 0.70 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL23426487 | 0.69 | IKBKB (0.48) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL30896675 | 0.69 | HTR2C (0.50) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL19510572 | 0.69 | CHRM2 (0.49) | HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD | 2005-12-29 | — | — | US | disclosed |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | APODACA RICHARD (US) | 2004-08-26 | — | — | US | disclosed |
| EP-1326863-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002024695-A2 | OCTAHYDRO-INDOLIZINES AND QUINOLIZINES AND HEXAHYDRO-PYRROLIZINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288323-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | SLC6A2 644/4885SLC6A4 288/4885SLC6A3 816/4885 |
| US-20030013733-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | SLC6A2 644/4885SLC6A4 288/4885SLC6A3 816/4885 |
| US-20040167336-A1 | Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine | HRH4, HNMT, HRH1 | SLC6A2 644/4885SLC6A4 288/4885SLC6A3 816/4885 |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | SLC6A2 555/4885SLC6A4 270/4885SLC6A3 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.